Departmental Papers (Dental)

Document Type

Journal Article

Date of this Version

5-2-1997

Publication Source

Journal of Biological Chemistry

Volume

272

Issue

18

Start Page

11706

Last Page

11709

DOI

10.1074/jbc.272.18.11706

Abstract

Platelet-activating factor (PAF) stimulates a diverse array of cellular responses through receptors coupled to G proteins that activate phospholipase C (PLC). Truncation of the cytoplasmic tail of the receptor to remove phosphorylation sites (mutant PAF receptor, mPAFR) results in enhancement of PAF-stimulated responses. Here we demonstrate that PAF or phorbol 12- myristate 13-acetate (PMA) pretreatment inhibited wild type PAFR-induced PLC- mediated responses by ~90%, whereas these responses to the phosphorylation- deficient mPAFR were inhibited by ~50%, despite normal G protein coupling, suggesting a distal inhibitory locus. PAF and PMA, as well as a membrane permeable cyclic AMP analog, stimulated phosphorylation of PLCβ3. A protein kinase C (PKC) inhibitor blocked phosphorylation of PLCβ3 stimulated by PAF and PMA but not by cAMP. Activation of protein kinase A (PKA) by cAMP did not result in inhibition of Ca2+ mobilization stimulated by PAF. In contrast, cAMP did inhibit the response to formylpeptide chemoattractant receptor. These data suggest that homologous desensitization of PAF-mediated responses is regulated via phosphorylation at two levels in the signaling pathway, one at the receptor and the other at PLCβ3 mediated by PKC but not by PKA. Phosphorylation of PLCβ3 by PKA could explain the inhibition of formylpeptide chemoattractant receptor signaling by cAMP. As PAF and formylpeptide chemoattractant receptors activate PLC via different G proteins, phosphorylation of PLCβ3 by PKC and PKA could provide distinct regulatory control for classes of G protein-coupled receptors.

Download

Included in

Dentistry Commons

Share

COinS
 

Date Posted: 08 December 2022

This document has been peer reviewed.